Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qishen Granules for Coronary Artery Disease-Related HFrEF (Qi Deficiency, Blood Stasis, Toxin Pattern)
CTR20254652Phase 2Active
- Sponsor
- Beijing Tong Ren Tang
- Start
- Dec 2025
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Qishen Huoxue Granules in heart failure with reduced ejection fraction (HFrEF), coronary arteriosclerosis, sponsored by Beijing Tong Ren Tang. Started Dec 2025; status: active.
02
Drugs
Qishen Huoxue Granules
03
Conditions
heart failure with reduced ejection fraction (HFrEF)coronary arteriosclerosis
Beyond the preview
Go deeper on CTR20254652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254652.